TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15054441

Group type: EXPERIMENTAL
Intervention: Instant coffee (5 g, approximately 50 mg trigonelline)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Trigonelline (50 mg)
Number of subjects: 8
Study: 11166143

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Conventional-dose therapy
Number of subjects: 1668
Study: 9164822

Group type: EXPERIMENTAL
Intervention: Smoking (heavy smokers: more than 20 cigarettes/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 57

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 57
Study: 8189732

Group type: EXPERIMENTAL
Intervention: Alcohol (actual and expected doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective intoxication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postexperimental beliefs about the alcohol content of the beverage consumed
Number of subjects: 0
Study: 2438221

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (VBP regimen)
Number of subjects: 263
Study: 31653225

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28034894

Group type: EXPERIMENTAL
Intervention: 500 ml water ingestion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Angiopoietin-1 treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Angiopoietin-1 and 0.8% saline cotreatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: 500 ml normal saline ingestion
Number of subjects: 24

Group type: COMPARATOR
Intervention: 50 ml water ingestion
Number of subjects: 24
Study: 26663687

Group type: EXPERIMENTAL
Intervention: mirabegron 25 mg
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: mirabegron 50 mg
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: mirabegron 100 mg
Number of subjects: 842

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 842
Study: 23819337

Group type: EXPERIMENTAL
Intervention: Genetically engineered biological agents (GEBAs), primarily rituximab (n = 66) and infliximab (n = 31)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Genetically engineered biological agents (GEBAs)
Number of subjects: 107
Study: 21694461

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (after 8 weeks of low-dose vitamin D 1000 IU/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nasal insulin (60 IU qid for 48 hours after high-dose vitamin D)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (after high-dose vitamin D)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (after nasal insulin)
Number of subjects: 32
Study: 18318569

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 0
Study: 16153694

Group type: EXPERIMENTAL
Intervention: Intraperitoneal alpha-interferon (50 x 10(6) IU weekly for 6 doses)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 70
Study: 14502137

Group type: EXPERIMENTAL
Intervention: Colgel
Number of subjects: 71

Group type: COMPARATOR
Intervention: Surgicel
Number of subjects: 71
Study: 10920049

Group type: EXPERIMENTAL
Intervention: random motion
Number of subjects: 9

Group type: COMPARATOR
Intervention: static dots
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: coherent motion (expansion or 3-D surface)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: coherent motion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: curved surface rotating in depth
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: curved 3-D surfaces
Number of subjects: 9
Study: 9377133

Group type: EXPERIMENTAL
Intervention: Cisapride (1.4‐2.3 mg/kg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 33
Study: 8266226

Group type: EXPERIMENTAL
Intervention: 20 micrograms dose of hepatitis B vaccine
Number of subjects: 320

Group type: COMPARATOR
Intervention: 10 micrograms dose of hepatitis B vaccine
Number of subjects: 320
Study: 3512919

Group type: EXPERIMENTAL
Intervention: Prostacyclin (12.5 ng/kg/min from heparinization until cardiopulmonary bypass, 25 ng/kg/min during bypass)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Buffer/diluent (Control)
Number of subjects: 100
Study: 31114673

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) and home exercise
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise and home exercise
Number of subjects: 241

Group type: COMPARATOR
Intervention: Home exercise alone
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: All groups (SMT, supervised rehabilitative exercise, home exercise)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Combination groups (SMT + home exercise, supervised rehabilitative exercise + home exercise)
Number of subjects: 241
Study: 29990345

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (rehabilitation)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (enabling)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (review)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (assessment)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (supportive)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (activity to support therapy)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (overall therapy received)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (delivery personnel)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (session type)
Number of subjects: 278
Study: 27485453

Group type: EXPERIMENTAL
Intervention: CY 2 g/m(2) + G-CSF (arm A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: G-CSF alone (arm B)
Number of subjects: 80
Study: 24862733

Group type: EXPERIMENTAL
Intervention: HVAD with ICD
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HVAD with history of VAs
Number of subjects: 41

Group type: COMPARATOR
Intervention: HVAD without history of VAs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HVAD with inappropriate ICD intervention
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: HVAD and ICD therapy
Number of subjects: 41
Study: 22546751

Group type: EXPERIMENTAL
Intervention: Osteopathy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham osteopathy
Number of subjects: 30
Study: 20622657

Group type: EXPERIMENTAL
Intervention: Lightweight mesh (Vypro II)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lightweight mesh (TiMesh)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard polypropylene mesh (Marlex)
Number of subjects: 59
Study: 18299182

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 15878732

Group type: EXPERIMENTAL
Intervention: Auditory signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right temporal lobe resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 0
Study: 12595837

Group type: EXPERIMENTAL
Intervention: Front-loaded alteplase (t-PA)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK-tPA)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lanoteplase (n-PA)
Number of subjects: 73
Study: 10228084

Group type: EXPERIMENTAL
Intervention: Shigella sonnei conjugate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a conjugate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shigella flexneri 2a conjugate (revaccination at 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Shigella conjugates
Number of subjects: 0
Study: 8739828

Group type: EXPERIMENTAL
Intervention: Water enema CT
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard CT
Number of subjects: 121
Study: 8100914

Group type: EXPERIMENTAL
Intervention: Low-dose allopurinol (25 mg on alternative days) plus triple immunosuppression (cyclosporin, prednisolone, azathioprine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Triple therapy alone (cyclosporin, prednisolone, azathioprine)
Number of subjects: 12
Study: 2953224

Group type: EXPERIMENTAL
Intervention: ramipril
Number of subjects: 15

Group type: COMPARATOR
Intervention: captopril
Number of subjects: 15
Study: 31718499

Group type: EXPERIMENTAL
Intervention: Greedy Rabbit (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo version of Greedy Rabbit (control group)
Number of subjects: 60
Study: 30287708

Group type: EXPERIMENTAL
Intervention: Prime fill flow
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dyad flow
Number of subjects: 2
Study: 26947216

Group type: EXPERIMENTAL
Intervention: Telehealth by an interprofessional team (n=451)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Usual care (n=150)
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Telehealth by an interprofessional team
Number of subjects: 601
Study: 25603438

Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.1%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Balanced salt solution placebo
Number of subjects: 62
Study: 23335738

Group type: EXPERIMENTAL
Intervention: Anidulafungin (200 mg loading dose on day 1, followed by 100 mg daily maintenance dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Anidulafungin (150 mg daily maintenance dose for 240-kg patient)
Number of subjects: 21

Group type: COMPARATOR
Intervention: General patient population and healthy subjects (historical data)
Number of subjects: 21
Study: 20638765

Group type: EXPERIMENTAL
Intervention: 4-stage teaching technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2-stage teaching technique
Number of subjects: 120
Study: 18808338

Group type: EXPERIMENTAL
Intervention: 3.75 microg of HA with AlOH
Number of subjects: 600

Group type: COMPARATOR
Intervention: 3.75 microg of HA without AlOH
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 7.5 microg of HA with AlOH
Number of subjects: 600

Group type: COMPARATOR
Intervention: 7.5 microg of HA without AlOH
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 15 microg of HA with AlOH
Number of subjects: 600

Group type: COMPARATOR
Intervention: 15 microg of HA without AlOH
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 45 microg of HA with AlOH
Number of subjects: 600

Group type: COMPARATOR
Intervention: 45 microg of HA without AlOH
Number of subjects: 600
Study: 16835748

Group type: EXPERIMENTAL
Intervention: Octreotide (30 mg) alone monthly
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Octreotide (30 mg) in combination with rofecoxib (up to 50 mg bid daily)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Combined univariate group analysis
Number of subjects: 71

Group type: COMPARATOR
Intervention: Multivariate analysis
Number of subjects: 71
Study: 12515744

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance
Number of subjects: 144

Group type: COMPARATOR
Intervention: Angiographic guidance
Number of subjects: 144
Study: 9922303

Group type: EXPERIMENTAL
Intervention: OAC group (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: OMC group (20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin)
Number of subjects: 539

Group type: COMPARATOR
Intervention: AC group (1000 mg amoxicillin, 500 mg clarithromycin)
Number of subjects: 539

Group type: COMPARATOR
Intervention: MC group (400 mg metronidazole, 250 mg clarithromycin)
Number of subjects: 539
Study: 7917508

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) administered immediately after astemizole ingestion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multiple doses of activated charcoal (12 g) administered twice daily for 8 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Astemizole with water only (control)
Number of subjects: 21
Study: 2589274

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 823828

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31934821

Group type: EXPERIMENTAL
Intervention: Nattospes as an adjuvant to standard of care (SOC) treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Nattospes as an adjuvant to SOC treatment
Number of subjects: 61
Study: 30818772

Group type: EXPERIMENTAL
Intervention: Parent-based primary care intervention with physician health-behavior counseling and four visits with a registered dietitian nutritionist over 6 months
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Parent-based primary care intervention
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 165
Study: 28171877

Group type: EXPERIMENTAL
Intervention: Lutein plus other antioxidants
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25156179

Group type: EXPERIMENTAL
Intervention: PEG-Asc
Number of subjects: 130

Group type: COMPARATOR
Intervention: SPS-Mg
Number of subjects: 130
Study: 23485073

Group type: EXPERIMENTAL
Intervention: Tension-band plating hemiepiphysiodesis (n = 10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Stapling hemiepiphysiodesis (n = 10)
Number of subjects: 26
Study: 21472620

Group type: EXPERIMENTAL
Intervention: Combined electrostimulation and biofeedback device (Myo 420™)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy (FitVibe medical™)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standardised rehabilitation therapy with pelvic floor re-education (control group)
Number of subjects: 75
Study: 17881186

Group type: EXPERIMENTAL
Intervention: Aspirin 100mg plus long-acting propranolol 80mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Aspirin 100mg plus placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol 80mg plus placebo
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 64
Study: 16516595

Group type: EXPERIMENTAL
Intervention: Low-level, home-based walking program for 24 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low-level, home-based walking program
Number of subjects: 99
Study: 15292895

Group type: EXPERIMENTAL
Intervention: Disinfectable, needle-free connector
Number of subjects: 243

Group type: COMPARATOR
Intervention: 3-way stopcocks
Number of subjects: 243
Study: 10890309

Group type: EXPERIMENTAL
Intervention: Paroxetine (SSRI)
Number of subjects: 13
Study: 9008456

Group type: EXPERIMENTAL
Intervention: rTOF patients with documented VT (group 1)
Number of subjects: 99

Group type: COMPARATOR
Intervention: nontetralogy control subjects (group 4 and group 5)
Number of subjects: 99
Study: 7706598

Group type: EXPERIMENTAL
Intervention: Restricted intake of thiamin, riboflavin, and vitamin B6 (daily diet providing no more than 55% of the Dutch RDA for these vitamins)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular intake of vitamins (supplemented at twice the RDA level)
Number of subjects: 24
Study: 3688396

Group type: EXPERIMENTAL
Intervention: Manual needling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (10 Hz for 5 minutes at P6 point)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclizine 50 mg
Number of subjects: 0
Study: 29282844

Group type: EXPERIMENTAL
Intervention: Incentive Care Scheme (ICS)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both ICS and UC
Number of subjects: 140
Study: 28441962

Group type: EXPERIMENTAL
Intervention: Peer health navigation intervention
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Smartphone application conducting ecologic momentary assessment (EMA)
Number of subjects: 19
Study: 24431099

Group type: EXPERIMENTAL
Intervention: Neck extension (group I)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No neck extension (group II)
Number of subjects: 180
Study: 24090588

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg per day in month 1, 20 mg per day in month 2, and 20-40 mg per day in months 3-12)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 21432860

Group type: EXPERIMENTAL
Intervention: Azelnidipine 16 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neither drug
Number of subjects: 30
Study: 19035858

Group type: EXPERIMENTAL
Intervention: Degarelix 240/80 mg
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Degarelix 240/160 mg
Number of subjects: 610

Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 610
Study: 16985018

Group type: EXPERIMENTAL
Intervention: 12-month exercise intervention of moderate-to-vigorous aerobic exercise, 60 minutes per day, 6 days per week
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study: 14689411

Group type: EXPERIMENTAL
Intervention: Pyruvate-fortified cardioplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lactate-based cardioplegia
Number of subjects: 30
Study: 10994865

Group type: EXPERIMENTAL
Intervention: Aircast SportStirrup (braced condition)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonbraced control
Number of subjects: 25
Study: 8799526

Group type: COMPARATOR
Intervention: Artemisinin monotherapy (500 mg single dose followed by another 500 mg on day 1 and then 250 mg twice daily for 4 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Artemisinin in combination with mefloquine (500 mg single dose followed by 750 mg on day 1 and then 250 mg three times daily for one more day; Mefloquine 250 mg three times daily for the first day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Artemisinin monotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Artemisinin in combination with mefloquine
Number of subjects: 38
Study: 1633906

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (group A) - intravenous hydrocortisone, 100 mg immediately after ultrasound-directed oocyte recovery, followed by prednisolone, 10 mg three times per day for 5 days, then 10 mg two times a day for 3 days, and 10 mg/d for 2 days.
Number of subjects: 31

Group type: COMPARATOR
Intervention: No glucocorticoid treatment (group B).
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups received luteal support with intramuscular injections of gestone 100 mg/d.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (group A)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No glucocorticoid treatment (group B)
Number of subjects: 31
Study: 6640552

Group type: EXPERIMENTAL
Intervention: Human lymphoblastoid interferon at a dose of 3.0 X 10(6) units/m2 three times/week for 6 weeks, followed by maintenance treatment with interferon (3.0 X 10(6) units/m2 once/week) for those who did not progress.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo maintenance (no further treatment) for patients who did not progress after initial treatment.
Number of subjects: 19
Study: 31739859

Group type: EXPERIMENTAL
Intervention: Wakemeter (haptic stimuli device)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Actigraphy
Number of subjects: 20
Study: 30397681

Group type: EXPERIMENTAL
Intervention: Fast food consumption
Number of subjects: 300
Study: 26956166

Group type: COMPARATOR
Intervention: Cholecalciferol 600 IU/day
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 3000 IU/day
Number of subjects: 280
Study: 25352435

Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 3

Group type: COMPARATOR
Intervention: Glycerol control
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 3
Study: 21443602

Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg once daily for 12 or 24 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alitretinoin 10 mg once daily for 12 or 24 weeks
Number of subjects: 32
Study: 19840748

Group type: EXPERIMENTAL
Intervention: 1g daily vitamin C treatment (Group II)
Number of subjects: 392

Group type: COMPARATOR
Intervention: No vitamin C treatment (Group I)
Number of subjects: 392
Study: 16490844

Group type: EXPERIMENTAL
Intervention: Anti-CTLA-4 monoclonal antibody (up to 9 mg/kg every 3 weeks)
Number of subjects: 63
Study: 15070003

Group type: EXPERIMENTAL
Intervention: Neglect patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study: 10927048

Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Leuprorelin acetate (3.75 mg)
Number of subjects: 54
Study: 9489383

Group type: EXPERIMENTAL
Intervention: Rhinocort-Nasal Aerosol
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Rhinocort-Nasal Turbuhaler
Number of subjects: 79
Study: 8222654

Group type: EXPERIMENTAL
Intervention: Cu-T 220 IUD
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: SS-IUD
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 87

Group type: COMPARATOR
Intervention: All IUDs
Number of subjects: 87

Group type: COMPARATOR
Intervention: Bleeders vs Non-bleeders
Number of subjects: 87
Study: 3530417

Group type: EXPERIMENTAL
Intervention: Aerochamber
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Spacer
Number of subjects: 24

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trial period
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 24
Study: 4646510

Group type: EXPERIMENTAL
Intervention: Active treatment (emphasizing good prognosis, early mobilization, physiotherapy)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Active treatment (physiotherapy)
Number of subjects: 178